TY - JOUR
T1 - Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
AU - Yang, Katherine S.
AU - Im, Hyungsoon
AU - Hong, Seonki
AU - Pergolini, Ilaria
AU - Del Castillo, Andres Fernandez
AU - Wang, Rui
AU - Clardy, Susan
AU - Huang, Chen Han
AU - Pille, Craig
AU - Ferrone, Soldano
AU - Yang, Robert
AU - Castro, Cesar M.
AU - Lee, Hakho
AU - Del Castillo, Carlos Fernandez
AU - Weissleder, Ralph
N1 - Publisher Copyright:
© The Authors, some rights reserved;.
PY - 2017/5/24
Y1 - 2017/5/24
N2 - Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.
AB - Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=85020031290&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aal3226
DO - 10.1126/scitranslmed.aal3226
M3 - Article
C2 - 28539469
AN - SCOPUS:85020031290
SN - 1946-6234
VL - 9
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 391
ER -
